Assessment of sensitivity and therapeutic response to next-line therapy in Chronic Myeloid Leukaemia (CML)

Response Post Tyrosine Kinase Inhibitor: Assesment of sensitivity and therapeutic response to next-line therapy in Chronic Myeloid Leukaemia (CML).

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ANZCTR

Registry ID

ACTRN12610000055000

Acronym

CML10 RESIST

Enrollment

679

Registered

2010-01-19

Start date

2010-06-08

Completion date

2015-11-30

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The target population for this study includes CML patients of any age residing in Australia or New Zealand with CML who have stopped TKI for any reason. Patients will be observed by there regular clinician and data submitted to the central trial coordinating centre.

Interventions

This an observational study, collecting data at regular intervals (6monthly) on subjects for five years. Observing current treatment, change in treatment and rationale for change

Eligibility

Sex/Gender

All

Age

0 to No maximum

Healthy volunteers

Inclusion criteria

Patients of any age Currently recieving Tyrosine Kinase Inhibitor(TKI) Patients with Philadelphia Positive or Breakpoint Cluster Region (BCR) V-abl Abelson murine leukaemia viral oncogene homolog1 (ABL) confirmed CML. Patients in any phase of CML including those with relapsed CML following allogeneic stem cell transplantation Patients who can provide written informed consent. Minors must have parental/legal guardian consent and assent where required

Exclusion criteria

If in the investigator's opinion the patient is unlikely candidate for follow-up information due to unavailability. Previous enrolment to the same registry.

Outcome results